This is an observational, non-interventional, single-country, multi center, retrospective cohort study, based on real world data collection, of patients with locally advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC) who had been treated with Afatinib at any line.
This is an observational, non-interventional, single-country, multicenter, retrospective cohort study, based on real world data collection, of patients with locally advanced or metastatic EGFR mutation-positive NSCLC who had been treated with Afatinib s at any line. The study is carried out by hospital-based oncologists/pneumonologists specializing in lung cancer under real-world conditions of daily clinical practice. Investigators were selected through a documented and structured feasibility process which accounted for physicians' qualifications, previous participation and experience in similar clinical studies, recruitment potential, and retention capability. In addition, in order to represent variations in current real-world patterns of care, research sites were recruited from various geographic regions in Greece, also taking into consideration the regional setting and type of healthcare site/institution (publicly/privately owned, specialized oncology/pulmonology clinic, university clinic).
Study Type
OBSERVATIONAL
Enrollment
59
Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC
Progression Free Survival
Progression Free Survival
Time frame: From Day 1 of treatment with Afatinib until disease progression, death from any cause or last follow-up, whichever occurs first, up to 12 months
Overall survival
Overall survival
Time frame: From Day 1 of treatment with Afatinib until death from any cause or last follow-up, up to 24 months
Second progression-free survival (PFS2)
Second progression-free survival (PFS2)
Time frame: From the initiation of next treatment following discontinuation of Afatinib to the date of progression, death or last contact, up to 6 months
Assessment of the safety profile of Afatinib
assessment of the safety profile of Afatinib
Time frame: In every cycle, every 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.